CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Tongli Pharmaceuticals (USA) Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Tongli Pharmaceuticals (USA) Inc
125 Maiden Ln Rm 309
Phone: (212) 797-9877p:212 797-9877 New York, NY  10038-4945  United States Fax: (302) 645-1280f:302 645-1280
This company is no longer actively traded on any major stock exchange.
Business Summary
Tongli Pharmaceuticals (USA), Inc. through its wholly owned subsidiary, Harbin Tianmu Pharmaceuticals Co., Ltd. (HTP), is a pharmaceutical company engaged in the production, manufacturing and distribution of both prescription and non-prescription over-the-counter (OTC) medicines in China. The company has the following types of productions: tablets, capsules, granules, oral liquid, etc, more than 10 types. The annual capacity of the company includes 300 million tablets, 250 million capsules, 10 million bags of granules and 36 million pipes of oral liquid. The Company’s products are Calcium Gluconate Oral Solution, Blood Circulation Peomotion Oral Solution, Antihyperlipidemics, Gynecologic Leucorrhea Stopping Tablet, Panax and Radix Polygoni Capsule, among others.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20133/31/2013YesYesYes--

Industries
SIC Code Description
2834 Pharmaceutical preparations
7389 Business services, not elsewhere classified
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer MingliYao 62 1/1/2009 3/1/2008
Chief Financial Officer LiLi 45 3/16/2009 3/16/2009
Corporate Secretary, Director AilingZhao 55 3/1/2008
Director YuanYao 32 12/23/2008 3/1/2008
Independent Director ZhijianHao 62 1/21/2011 1/21/2011

Business Names
Business Name
American Tony Pharmaceutical, Inc.
Harbin Lvnong Plant Ltd.
Harbin Tianmu Pharmaceuticals Co., Ltd.
Harbin Tongli Technoligy Co., Ltd.
TGLP
Tongli Pharmaceuticals (USA), Inc.

General Information
Number of Employees: 120 (As of 3/31/2012)
Outstanding Shares: 14,728,111 (As of 2/8/2014)
Shareholders: 468
Stock Exchange: OTC
Federal Tax Id: 841090791
Fax Number: (302) 645-1280


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023